Definium Therapeutics, Inc.

United States

Last price 37.96 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.10B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Defi...